title: [Emergency psychopharmacotherapy in Hungary -- preliminary data].
abstract: OBJECTIVE
  Although the number of patients admitted for psychiatric emergency care is increasing according to data from various countries, there are no large-scale studies assessing clinical emergency practice and in several countries no national guidelines have been published concerning emergency care in psychiatry. The aim of our study was to assess practice related to emergency care of agitated-psychotic patients in Hungary.
  
  
  METHODS
  Anonymous survey questionnaire with questions related to care of an agitated patient showing psychotic symptoms was dispatched to 210 institutions providing psychiatric care in Hungary in 2013.
  
  
  RESULTS
  The overwhelming majority of the 155 participating clinicians would use haloperidol (92.9%) and benzodiazepines (81.3%), 74.8% in a dual combination. 18.7% would apply monotherapy and 5.2% a triple combination of medications. 59.4% would use i.v. and 23.9% i.m. therapy, and 9% would apply the combination of these two. In case of failure of first-line therapy, 76.8% of participants would repeat the previous medication.
  
  
  CONCLUSIONS
  The aim of our study was to assess emergency interventions in psychiatry focusing on different psychopharmacological approaches. Our results provide a cross-sectional view on current practice in Hungary, and therefore may contribute to outlining practice-coherent guidelines and also provide the opportunity for a comparison with international trends.
authors.affiliation: SE Kútvölgyi Klinikai Tömb, Klinikai és Kutatási Mentálhigiénés Osztály, Budapest, Hungary. col.kovacs@gmail.com.
authors.forename: Andrea
authors.initials: A
authors.lastname: Szegő
authors.forename: Monika
authors.initials: M
authors.lastname: Eleméry
authors.forename: Gábor
authors.initials: G
authors.lastname: Faludi
authors.forename: Gábor
authors.initials: G
authors.lastname: Kovács
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use; D003006:Clopenthixol / Q000627:therapeutic use; D004329:Droperidol / Q000627:therapeutic use; D011307:Drug Prescriptions; D004359:Drug Therapy, Combination; D004638:Emergency Treatment / Q000379:methods*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006814:Hungary; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011398:Promethazine / Q000627:therapeutic use; D011570:Psychiatry / Q000379:methods / Q000706:statistics & numerical data; D011595:Psychomotor Agitation / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D003006:Clopenthixol; D011398:Promethazine; D006220:Haloperidol; D000077152:Olanzapine; D004329:Droperidol